Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biodesix Inc (NQ: BDSX )

1.650 +0.160 (+10.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 68,276
Open 1.510
Bid (Size) 1.600 (1)
Ask (Size) 1.650 (5)
Prev. Close 1.490
Today's Range 1.500 - 1.700
52wk Range 0.9550 - 2.530
Shares Outstanding 78,614,114
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer
From Biodesix, Inc.
Via Business Wire
Biodesix to Participate in Two Upcoming Investor Conferences in September
From Biodesix, Inc.
Via Business Wire

Performance

YTD
-19.51%
-19.51%
1 Month
+5.10%
+5.10%
3 Month
+36.36%
+36.36%
6 Month
-11.29%
-11.29%
1 Year
+29.92%
+29.92%

More News

Read More
Kingstone Companies And 3 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Recap: Biodesix Q1 Earnings
Via Benzinga
Biodesix Earnings Perspective: Return On Capital Employed
Via Benzinga
Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Second Quarter 2023 Results and Highlights
From Biodesix, Inc.
Via Business Wire
Top 5 Health Care Stocks That May Crash In Q3
Via Benzinga
Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Biodesix, Inc.
Via Business Wire
Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules
From Biodesix, Inc.
Via Business Wire
Why Shares of CareDx Are Jumping Friday
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services
From Biodesix, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting
From Biodesix, Inc.
Via Business Wire
Biodesix to Participate in William Blair’s 43rd Annual Growth Stock Conference
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing
From Biodesix, Inc.
Via Business Wire
Biodesix, Inc. Chief Financial Officer Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors
From Biodesix, Inc.
Via Business Wire
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference
From Biodesix, Inc.
Via Business Wire
Biodesix Announces First Quarter 2023 Results and Highlights
From Biodesix, Inc.
Via Business Wire
Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023
From Biodesix, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights
From Biodesix, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.